US-listed Chinese biotechs are switching auditors in hopes of satisfying the US securities regulator's demands - but legal experts also see other considerations at play.

The latest move signals a toughening stance in China over sensitive technology exports, as the bilateral relationship with the US continues its free fall.

A landmark approval and domestic tie-up in China mark the fast innovation that is shaping the country’s health sector.

The approval of China's second CAR-T therapy has come amid reimbursement challenges, despite the pricing of its direct competitor being much lower than in the US. Chinese developers are pinning their hopes on rapid domestic market expansion via commercial insurance tie-ups as other CAR-Ts move through local development.